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ABSTRACT
Objectives This study seeks to determine whether there is a higher rate of false positive serum screening for Down
syndrome in women with sickle cell anemia and, if so, which markers contribute to the false positive screen.
Methods This is a retrospective cohort study of women who had serum screening between 1998 and 2011. Subjects
were women with sickle cell anemia (n = 13), and controls were African American women who did not have that
disease (n = 91). The populations were compared using basic inferential statistics.
Results The positive screen rate was 38.5% (5/13) in women with sickle cell anemia and 7.7% (7/91) in the control
population (odds ratio 7.5, 95% confidence interval 1.6–35.8, P = 0.001). At the average age of the cases (25 years), the
expected false positive rate is only 2%. The human chorionic gonadotrophin values were significantly higher in cases
than controls (2.00 and 1.30MoM, P = 0.017), whereas levels of other serum analytes were similar. None of the screen
positive results were associated with a fetus or neonate affected by Down syndrome.
Conclusions The false positive Down syndrome serum screen rate is significantly higher in patients with sickle cell
anemia than in African American women without that disease. The human chorionic gonadotrophin values were
significantly higher in cases than controls, suggesting that placental factors may contribute to the elevated false
positive rate. © 2015 John Wiley & Sons, Ltd.
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INTRODUCTION
Maternal serum screening is used to identify fetuses at risk for
a variety of common disorders, the most frequent of which is
Down syndrome.1,2 The California Prenatal Screening Program
provides prenatal screening to all women residing in the state
and has a false positive rate of 5% for Down syndrome.
Maternal age is a significant factor in the risk calculation:
women< 28 years old have a 2% risk of screening positive
whereas women over age 40 years have a screen positive rate
of >20%.
After the advent of serum screening for birth defects, it
became evident that pregnancies with abnormal serum
analytes have increased risk of an underlying abnormal
placentation and related clinical manifestations. Specifically,
low pregnancy-associated plasma protein A (PAPP-A), and
estriol, and elevated alpha-fetoprotein (AFP), human chorionic
gonadotrophin (hCG), and inhibin A are associated with
preeclampsia, fetal growth restriction, and preterm birth.3
This study was conceived when we noticed that women
referred to the University of California, Davis, prenatal
diagnosis program for sickle cell anemia had high rates of false
positive prenatal screening results for Down syndrome. We
hypothesize that these pregnancies may be at increased risk
of placental insults because of sickle cell disease and may thus
be at an increased risk for abnormal serum screening results.
Our study has two objectives: to determine whether women
with sickle cell anemia have a higher rate of false positive
prenatal screening for Down syndrome and, if so, to determine
which serum markers contribute to these false positive
screens. This information may be helpful in counseling women
with sickle cell anemia as they decide what kind of prenatal
screening to pursue.
MATERIALS AND METHODS
This is a retrospective cohort study that was approved by the
institutional review board of the Office of Research at the
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University of California, Davis. Since 1994, the UC Davis
Department of Obstetrics and Gynecology has maintained a
database for quality assurance purposes of all women seen
for prenatal genetic counseling and testing. The department
maintains a separate database of all women seen in the high
risk obstetrics clinic; all patients with sickle cell anemia in
prenatal care at UC Davis would have been seen in this clinic.
Thus, ascertainment of all cases with sickle cell disease is
ensured by using both data sets. We used the portion of this
dataset that includes women seen from 1998 to 2011 to identify
cases and controls. We chose 1998 as the starting date, because
that was the first year in which a patient with sickle cell anemia
had serum screening. Each patient was used as a subject only
once; if she had more than one pregnancy during the study
period, we used the data from the earlier pregnancy. We
excluded patients with multiple gestations.
Cases and controls were identified from these two data sets.
Cases were comprised of those women with sickle cell anemia
who had prenatal serum screening performed. All of these
women were African American. The controls were all African
American women without sickle cell disease who had serum
screening and were seen in prenatal diagnosis or had care in
the high risk obstetrics clinic. We identified these patients for
the control group by searching our prenatal genetic counseling
database and our high risk obstetrics clinic database for African
American women and included those who had serum screening.
For each case and control, we collected information from the
databases including age, Down syndrome risk, and the value of
each serum analyte measured in multiples of the median
(MoM). We collected values for second-trimester AFP, hCG,
estriol, and inhibin A and, when available, first-trimester
PAPP-A and free ß-hCG. Whenever serum screen results were
missing from the database, a review of the patient’s institutional
medical record was conducted. Serum screen results that could
not be obtained through these avenues were requested directly
from the California Prenatal Screening Program. Not all serum
analyte values were available for all women. Patients with no
Down syndrome risk documented were excluded.
A positive Down syndrome serum screen was defined by the
cutoff used in the California Prenatal Screening Program. For
second-trimester quad screening, this was 1 in 200. For all
patients with a positive screen, a review of the mother’s and
infant’s charts was conducted to determine whether the infant
had Down syndrome. This allowed us to determine whether
the screen was falsely or truly positive.
The false positive serum screen rate was then calculated for the
case population and the control population, and the rates
compared using a chi-squared test. Mean second-trimester
serum analyte values were calculated for cases and controls and
compared using a two-sample t-test assuming equal variances.
Because only two of the cases had first-trimester screening, we
did not calculate means for PAPP-A or first-trimester hCG.
RESULTS
Of the 13 women with sickle cell anemia, five (38.5%) had a
positive Down syndrome screen. Of those with a positive
screen, four had normal karyotype by amniocentesis. One
woman declined amniocentesis, and chart review revealed that
her infant had no clinical manifestations of Down syndrome
(Table 1).
We identified 91 women for our control population. Of these,
seven (7.7%) had a positive Down syndrome screen. Of those
with a positive screen, five could be confirmed as definite false
positives, two because of normal karyotype and three by chart
review (Table 2). The other two were assumed to be false
positives as both had a Down syndrome risk ≤ 1%. Maximizing
Table 1 Cases: patients with sickle cell anemia
Age T21 risk
Serum analytes (MoM)
GA at delivery NotesAFP hCG uE3 Inhibin
Case 1 23 1 : 400 1.04 0.96 0.61 0.87 39 weeks 2 days
Case 2 20 1 : 10 000 0.88 0.89 1.55 38 weeks 5 days
Case 3 19 1 : 770 0.68 0.97 0.67 Unknown
Case 4 20 1 : 1300 0.70 1.40 0.99 37 weeks 2 days IUGR
Case 5 20 1 : 100 000 1.11 0.53 0.91 0.87 37 weeks 0 days
Case 6 20 1 : 140 0.49 2.39 0.85 0.93 38 weeks 6 days No karyotype performed;
Infant without T21
Case 7 34 1 : 870 0.86 1.11 0.93 Unknown
Case 8 24 1 : 10 0.48 6.39 0.36 39 weeks 4 days 46,XX by amniocentesis
Case 9 30 1 : 60 1.2 3.97 0.97 4.97 20 weeks 2 days Pregnancy terminated for social reasons;
karyotype from outside institution
reportedly normal
Case 10 35 1 : 1300 .91 1.59 1.92 0.89 40 weeks 0 days
Case 11 32 1 : 33 1.99 3.54 0.28 15 weeks 1 day IUFD; 46,XX by amniocentesis
Case 12 28 1 : 19 1.84 1.86 0.30 2.93 20 weeks 0 days IUFD; 46,XY by amniocentesis
Case 13 19 1 : 10 000 0.84 0.35 1.89 36 weeks 2 days Severe preeclampsia
AFP, elevated alpha-fetoprotein; hCG, human chorionic gonadotrophin; GA, gestational age; IUGR, intrauterine growth restriction; IUFD, intrauterine fetal demise.
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the false positive rate in this way makes it less likely that the
false positive rate for the control group would be
underestimated, and less likely that the significant difference
between rates in cases and controls would be overstated.
The rate of false positive screens was significantly higher in
women with sickle cell anemia than controls: odds ratio 7.5,
95% confidence interval 1.6–35.8, P = 0.001 (Table 2). For
women age 18–28 years in California, the expected screen
positive rate is 2%, thus both cases and controls had a higher
than expected screen positive rate.
Table 3 displays the characteristics of the two groups.
Among serum analytes, hCG levels were significantly higher
in women with sickle cell anemia than in controls. There was
also a trend toward higher inhibin in cases than in controls.
AFP and estriol values were similar in the two populations.
Among the 13 cases, there were seven deliveries at greater
than 37weeks gestational age and one preterm delivery at
36weeks 2 days gestational age. There were two intrauterine
fetal demises, at 17 and 20weeks, both with normal karyotypes.
One patient electively terminated her pregnancy at 20weeks
gestation for reasons unrelated to the fetal Down syndrome
risk; she did have an amniocentesis at an outside institution,
but the result is unknown. Two of the pregnancy outcomes
are unknown. The five cases with false positive screens
included two women with term deliveries, the terminated
pregnancy, and the two fetal deaths.
There was one patient with preeclampsia among the 13
cases; her serum screen was negative. One infant had a birth
weight less than the tenth percentile for gestational age,
weighing 2440 g at 37weeks gestational age; her serum screen
was also negative.
DISCUSSION
This study reveals that women with sickle cell disease have an
increased chance of having a positive serum screen for Down
syndrome, with a risk approaching 40%. Only the hCG analyte
was significantly greater in cases than controls; however,
inhibin had a trend toward significance.
Although our study design does not substantiate conclusions
about the mechanism of these findings, the analyte differences
found are consistent with what is seen in pregnancies with
placentation abnormalities. The underlying placentation
problem with sickle cell disease is thought to be from placental
hypoxia rather than a decidual or spiral arteriole invasion
abnormality.4 Both inhibin A and hCG are produced in the
syncytiotrophoblast, thus these two markers would be
potentially affected by a similar insult in placental development.
Hypoxia can induce cytotrophoblast proliferation and increased
hCG production. Increased cytotrophoblast proliferation has
also been noted in placentas of women with sickle disease.5
Thus, sickle cell disease could plausibly be associated with
elevations in these two serum analytes.
If trophoblast proliferation is the underlying reason for
increased hCG and inhibin A, we might not have expected to see
changes in serum AFP or estriol. AFP is solely produced by the
fetus and may be elevated when the placenta is more permeable,
increasing diffusion into the maternal blood stream. The fetal
precursor of estriol, 16-OH estrone sulfate, is converted by steroid
sulfatase in the syncytiotrophoblast to estriol. Estriol is a dual fetal
and placental product that tends to be low in pregnancies with
disorders related to placentation abnormalities.3
There are a couple of major limitations to this study in
addition to it being a retrospective cohort study with a small
Table 2 Control patients with positive serum screen
Age T21 risk
Serum analytes (MoM)
GA at Delivery NotesAFP hCG uE3 Inhibin
Patient 1 23 1 : 38 1.77 2.82 0.39 1.18 27 weeks 4 days Infant without T21
Patient 2 36 1 : 31 0.89 2.91 0.73 0.33 38 weeks 1 day Infant without T21
Patient 3 38 1 : 100 1.59 1.73 0.61 39 weeks 2 days Infant without T21
Patient 4 40 1 : 24 0.83 1.64 0.66 39 weeks 1 day 46,XX by amniocentesis
Patient 5 42 1 : 20 1.13 1.24 0.39 36 weeks 5 days 46,XY by amniocentesis
Patient 6 31 1 : 100 0.84 0.67 0.40 Unknown
Patient 7 40 1 : 150 0.76 1.01 0.97 Unknown
AFP, elevated alpha-fetoprotein; hCG, human chorionic gonadotrophin; GA, gestational age.
Table 3 Comparison of serum analyte values
Cases (n = 13) Controls (n = 91) RR (95% CI) P-value
Positive screen 5 (38.5%) 8 (7.7%) 7.50 (1.60–35.8) 0.0014
Maternal age 24.9 ± 5.29 26.8 ± 5.29 0.313
AFP MoM (mean ± SD) 1.00 ± 0.44 1.09 ± 0.39 0.47
hCG MoM (mean ± SD) 2.00 ± 1.65 1.30 ± 0.76 0.017
Estriol MoM (mean ± SD) 0.94 ± 0.53 0.95 ± 0.30 0.914
Inhibin A MoM (mean ± SD) 1.70 ± 1.53 1.08 ± 0.51 0.114
RR, relative risk; CI, confidence interval; AFP, alpha-fetoprotein; hCG, human chorionic gonadotrophin; SD, standard deviation.
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number of subjects. We feel we had good ascertainment of all
women with sickle cell disease seen at our institution.
However, the control group was identified from both the high
risk and prenatal database and does not reflect the general
obstetrical population, thus there likely was enrichment for
African American women with a positive Down syndrome
screen. This would explain why 7.7% of the control population
had a positive screen as opposed to the expected 2% for the
general population based on the average age. Despite this
higher than expected number of positive screens in the control
population, we found a significant difference.
A second limitation is that serum screening in California
changed twice during the course of the study, going from triple
marker at the beginning of the time period, to quad screening in
2007, and then sequential screening in 2009. This then limited
the number of cases (and controls) with inhibin A
measurements. We found a trend toward significant differences
with inhibin A, which may have been significant had this been
measured throughout the entire study time frame. The limited
data on first-trimester cases prevents finding an association
with false positive first-trimester screens.
This study should be used as an aid in counseling women with
sickle cell disease who have a positive serum screen for Down
syndrome. This does not negate the possibility of the fetus actually
having Down syndrome, but it can help give an explanation about
why the test was positive. Further study is needed to determine if
the risk for placenta-related disorders can be further defined using
these maternal serum screening values, as pregnancies in women
with sickle cell disease are well known to be at increased risk
for preeclampsia6 and fetal growth restriction.7 This study should
also provide guidance when counseling women about the
interpretation of their prenatal screening results.
WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• There are no previously published studies on the effect of sickle cell
anemia on accuracy of maternal serum genetic screening.
WHAT DOES THIS STUDY ADD?
• Maternal serum second-trimester genetic screening has a high false
positive rate in women with sickle cell anemia.
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